PGDx's LungSelect

Personal Genome Diagnostics has launched LungSelect, a next-generation sequencing assay that detects a panel of the most common, clinically actionable genetic alterations — including somatic sequence mutations and translocations — in the plasma of non-small cell lung cancer patients. 

The liquid biopsy test is able to detect sequence mutations and translocations at frequencies as low as 0.02 percent and 0.1 percent respectively, with sensitivity greater than 90 percent. The mutations covered are associated with sensitivity or resistance to approved therapies, and could also guide patients to clinical trials of experimental drugs.